A promising new autologous stem cell therapy for Alzheimer’s disease has moved to Phase 2 clinical trials following positive early results. The treatment, developed by Regeneration Biomedical, involves harvesting a patient’s own stem cells and delivering them directly to the brain via a specialized reservoir. Early data suggests the therapy may help regenerate damaged neural tissue and slow cognitive decline, offering a potential new avenue for treating neurodegenerative conditions where drug-based therapies have struggled.
Source: CGTLive
Link: https://www.cgtlive.com/view/cgtlive-weekly-rewind-december-5-2025







Leave a Reply